Category: 58142-46-4

On June 7, 2022, Tang, Feng; Li, Zhen; Zhang, Guobao; Zhou, Feng; Chen, Ping; Ren, Jinsheng published a patent.Product Details of 58142-46-4 The title of the patent was Preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and application for treating KRAS G12C mutant tumors. And the patent contained the following:

The present invention relates to the preparation of (piperazinyl)tetrahydropyridopyrimidine derivatives and uses thereof. In particular, (piperazinyl)tetrahydropyridopyrimidine derivatives I (R is -C(R6)=CH(R7), furanyl, -CH(F)(Cl), etc.; Q is selected from C=O or S(=O)2; R1 is selected from heterocyclyl or NR4R5; R2 is selected from aryl or heteroaryl; R3 is selected from hydrogen or NC-CH2; R4 and R5 are independently selected from hydrogen, alkyl, aryl or heteroaryl, alkylacyl, C1-4 alkyloxyacyl, or R4 and R5 together with the nitrogen atom to which they are attached form a heterocyclyl; R6 is selected from hydrogen or fluorine; R7 is selected from hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy, described C1-4 alkyl or C1-4 alkoxy is optionally by =O, halogen, C1-4 alkoxy, etc.; n is selected from 0, 1, 2; m is selected from 1, 2, 3) were prepared The inventive compounds or a pharmaceutically acceptable salts, pharmaceutical compositions are used in preparation of medicaments for preventing and/or treating KRAS G12C mutant tumors. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to piperazinyl tetrahydropyridopyrimidine preparation antitumor agent, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 14, 2005, Fernandes, Prabhavathi B.; Mailman, Richard Bernard; Nichols, David Earl; Postlethwait, Robert Neil published a patent.Computed Properties of 58142-46-4 The title of the patent was Preparation of dopamine D1 receptor agonists and co-administration with D2 receptor antagonists for treatment of neurological and psychiatric disorders. And the patent contained the following:

Methods for treating a patient having neurol., psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions The agonist is a compound selected from the group consisting of hexahydrobenzophenanthridines, hexahydrothienophenanthridines, phenylbenzodiazepines, chromenoisoquinolines, naphthoisoquinolines, and their analogs, derivatives and pharmaceutically acceptable salts; the synthesis of such compounds is disclosed. The dopamine D2 receptor antagonist is specifically claimed to be an antipsychotic agent. The pharmaceutical composition further comprise one or more cholinergic agents, cholinergic agonists, acetylcholine mimetics, acetylcholine esterase inhibitors, or combinations thereof. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Computed Properties of 58142-46-4

The Article related to dopamine receptor ligand neurol psychiatric disorder treatment, phenanthridine phenylbenzodiazepine isoquinoline analog preparation neurol disorder treatment, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.Computed Properties of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On October 31, 2017, Moon, Seong Yun; Kim, Seul Gi; Lee, Seon Hui; Choi, Yeon Hui; Park, Chi Hyeon published a patent.Application of 58142-46-4 The title of the patent was Preparation of condensed polycyclic compounds for organic electric device. And the patent contained the following:

Disclosed are compounds I [X = N-L1-R1, S, O, etc.; n, m = 0 or 1 such as m+n≥1 (when n or m is 0, then A or B, at each occurrence, represents a single bond); A, B = independently single bond, N-L2-R2, S, etc.; Z1-Z12 = independently CR3 or N with a proviso that at least one of Z1-Z12 is N; R1-R3 = independently H, aryl, fluorenyl, etc.; L1, L2 = single bond, arylene, fluorenylene, etc.] and electronic device thereby. For example, red electroluminescent device comprising II (phosphorescent host material) showed improvements in luminous efficiency, lifespan and driving voltage compared to device using CBP. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Application of 58142-46-4

The Article related to condensed polycycle preparation organic elec device material, Optical, Electron, and Mass Spectroscopy and Other Related Properties: Luminescence and other aspects.Application of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On October 22, 2020, Marx, Matthew Arnold; Christensen, James Gail; Smith, Christopher Ronald; Fischer, John P.; Burns, Aaron Craig published a patent.Recommanded Product: 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation of pyridopyrimidine derivatives as KRas G12C inhibitors for the treatment of KRas-mediated diseases. And the patent contained the following:

The invention relates to preparation of pyridopyrimidines, e.g., I, that inhibit KRas G12C. Thus, I was prepared via intermediate II. Pyridopyrimidines of the invention are irreversible inhibitors of KRas G12C (data given) and can be used in treatment of diseases that are KRas-mediated as well as caused by KRas G12C mutation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 4-Bromo-5-nitroisoquinoline

The Article related to pyridopyrimidine preparation kras g12c inhibitor disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 16, 2020, Marx, Matthew Arnold; Christensen, James Gail; Smith, Christopher Randolph; Fischer, John P.; Burns, Aaron Craig published a patent.Recommanded Product: 58142-46-4 The title of the patent was Preparation of pyrimidine derivatives as KRas G12C inhibitors for the treatment of KRas-mediated diseases. And the patent contained the following:

The invention relates to preparation of pyrimidines(I) that inhibit KRas G12C. Compounds I wherein X is a 4-12 membered saturated or partially saturated monocyclic, bridged, spirocyclic or fused bicyclic ring; Y is a bond, O, S, etc.; R2 is H, alkyl, alkoxy, etc.; L is bond, C(O), or C1-3 alkylene; R4 is H, aryl, cycloalkyl, etc.; etc., are claimed. The example compound II was prepared via multi-steps synthesis using 4,7-dichloropyrido[4,3-d]pyrimidine as starting material (procedure given). Compounds I are irreversible inhibitors of of KRas G12C (data given). Compounds I can be used in treatment of diseases that are KRas-mediated as well as caused by KRas G12C mutation. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 58142-46-4

The Article related to pyrimidine preparation kras g12c inhibitor disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On May 29, 1991, Gueremy, Claude; Malleron, Jean Luc; Mignani, Serge published a patent.Recommanded Product: 4-Bromo-5-nitroisoquinoline The title of the patent was Preparation and formulation of 2-[4-(indolylmethyl)piperidinoethyl]naphthoisothiazole-1,1-dioxides and analogs as serotonin (5HP) reuptake inhibitors. And the patent contained the following:

R1(CH2)nQ [I; Q = Z3R3, Z4R4; R1 = anellated isothiazolo groups Q1-Q3, RSO2N(Z), etc.; R = 2-naphthyl; R3 = 1-indenyl, 1-indanyl, (CH2)mR2, etc.; R2 = indolyl, indanyl, indenyl, quinolyl, etc.; R4 = (CH2)mR2; Y = H, alkyl, alkoxy, Ph; Z = alkyl; Z1 = SO2, CO; Z2 = CH; Z2 may also = N when Z1 = SO2; Z3 = piperidine-1,4-diyl; Z4 = piperazine-1,4-diyl, 1,2,3,6-tetrahydropyridine-1,4-diyl; m = 1, 2; n = 2, 3] were prepared Thus, BrCH2CH2Cl was condensed with 1,8-naphthosultam and the product condensed with 4-[(5-fluoro-3-indolyl)methyl]piperidine to give, after N-methylation, title compound II. I had IC50 < 25 nM for binding of paroxetine (substrate not given). The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 4-Bromo-5-nitroisoquinoline

The Article related to naphthoisothiazole indolylmethylpiperidinoethyl serotonin reuptake inhibitor, indolylmethylpiperidinoethylnaphthoisothiazole preparation serotonin reuptake inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 4-Bromo-5-nitroisoquinoline

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On January 10, 1990, Comte, Marie Therese; Gueremy, Claude; Malleron, Jean Luc; Mignani, Serge; Peyronel, Jean Francois; Truchon, Alain published a patent.Recommanded Product: 58142-46-4 The title of the patent was Preparation and formulation of (aza)naphthalenesultam derivatives as serotoninergic antagonists. And the patent contained the following:

Title compounds I [R1 = 4-(hetero)aryl-substituted 1,2,3,6-tetrahydro-1-pyridyl, 1-piperazinyl, or piperidino; R2, R3 = H, halo, R4 = H; or R2 = R4 = H, R3 = halo, AcNH; or R2 = R3 = H, R4 = halo, all with X = CH; or R2 = R3 = R4 = H, X = N; Z = (un)substituted alkylene; various provisos] were prepared as serotonergic 5-HT2 receptor antagonists (no data). Thus, N-alkylation of 1,8-naphthosultam by Br(CH2)3Cl using NaH in DMF gave the N-(3-chloropropyl) derivative, which reacted with 1-(4-fluorophenyl)piperazine in PhMe containing Et3N to give (piperazinylpropyl)naphthoisothiazole derivative II. Three formulations and 61 syntheses are given. The IC50 of I for displacement of [3H]-ketanserin from 5-HT receptors are said to be generally <25 nM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Recommanded Product: 58142-46-4

The Article related to naphthalenesultam preparation serotoninergic antagonist, naphthoisothiazole preparation 5ht antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On September 2, 2005, Yamada, Rintaro; Seto, Minoru published a patent.Related Products of 58142-46-4 The title of the patent was Preparation of isoquinoline derivatives as inhibitors of myosins light chain phosphorylation. And the patent contained the following:

The title compounds I [wherein R1 = H, halo, OH, NH2, or alkoxy; R2 = H, halo, alkyl, etc.; R3 = (un)substituted OH, NH2, or SO2NH2] or salts thereof are prepared as inhibitors of myosins light chain phosphorylation for the treatment of glaucoma, chronic obstructive pulmonary disease, asthma, etc. For example, the compound II•xHCl was prepared II•xHCl inhibited human myosins light chain phosphorylation with IC50 of 0.8 μM. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Related Products of 58142-46-4

The Article related to isoquinoline preparation inhibitor myosin regulatory light chain phosphorylation obstruction, human treatment glaucoma chronic obstructive pulmonary disease asthma, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Related Products of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On July 31, 1992, Werra, W.; Heber, D. published an article.Product Details of 58142-46-4 The title of the article was 1H and 13C NMR studies of substituted isoquinolinium derivatives in different solvents. And the article contained the following:

1H and 13C NMR data for 1-cyano-, 4-cyano-, 4-bromo- and 4-bromo-5-nitro-substituted isoquinolines, isoquinoline N-oxides and N-methoxy and N-Et salts in different solvents are reported. The substituent chem. shifts are discussed with regard to the reactivity of the N-methoxy compounds in the presence of nucleophilic reagents. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Product Details of 58142-46-4

The Article related to nmr isoquinolinium compound solvent effect, Physical Organic Chemistry: Resonance Spectra (Electron Spin, Nuclear Magnetic and Fourier Transform Nuclear Magnetic, Quadrupole, etc.) and other aspects.Product Details of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem

On November 30, 1989, Volovenko, Yu. M.; Litvinenko, S. V.; Babichev, F. S. published an article.Computed Properties of 58142-46-4 The title of the article was Annulation of benzoindolizine rings to quinoxaline nucleus. And the article contained the following:

Quinoxalineacetonitriles I (R3 = Me, Ph, or 4-MeC6H4) react with isoquinolines II (R1 = H, R2 = H, NO2; R1 = Br, R2 = NO2) 2-4 h in DMF at 160° or reflux to give quant. benzindolizinoquinoxalines III. The experimental process involved the reaction of 4-Bromo-5-nitroisoquinoline(cas: 58142-46-4).Computed Properties of 58142-46-4

The Article related to benzindolizinoquinoxalinecarbonitrile, indolizinoquinoxaline benz, quinoxaline benzindolizino, isoquinoline quinoxalineacetonitrile reaction, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Computed Properties of 58142-46-4

Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem